Anti-glaucoma eye drops linked to meibomian gland changes

Article

The long-term use of anti-glaucoma eye drops is linked to changes in meibomian gland morphology and function.

The long-term use of anti-glaucoma eye drops is linked to changes in meibomian gland morphology and function, according to a paper published in the journal Cornea.

Dr Reiko Arita et al., Department of Ophthalmology, University of Tokyo School of Medicine, Tokyo, studied 71 eyes of 71 glaucoma patients who were administered one type of anti-glaucoma eye drops (group 1), 61 eyes of 61 glaucoma patients (group 2) receiving two types of anti-glaucoma eye drops and 30 eyes of 30 glaucoma patients (group 3) receiving three types of anti-glaucoma eye drops. There was also a control group consisting of 75 eyes of 75 healthy participants.

Noncontact meibography was used to observe and score the meibomian glands of upper and lower eyelids. Slit lamp examination was used to evaluate lid margin and superficial punctate keratopathy, whilst a questionnaire was used to evaluate subjective symptoms. Tear film break-up time (TBUT) was assessed, along with meibum.

Glaucoma patients demonstrated significantly higher lid margin abnormality, superficial punctate keratopathy, meiboscore and meibum scores, compared to control participants. TBUT and Schirmer scores were significantly lower for glaucoma patients, compared to the control group.

It was found that meiboscore significantly correlated with lid margin abnormality score and TBUT in group 1, TBUT, symptom score and age in group 2 and lid margin abnormality score only in group 3.

For the abstract please click here.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.